Biotechnology companies have used this approach to develop the full potential of their intellectual property (see Nature Biotechnology, volume 22, pages 271-277, March 2004). As parent company, Signe BioPharma Inc will be the General Partner and "Protein Factory" for all related Limited Partnerships (LP) or Special Project Entities (SPE). Signe will use this structure to promote use of specific products and to enter innovative clinical and commercial areas that require high capacity production of complex proteins. With this structure, Signe benefits from revenue streams and equity in each new entity while at the same time remaining focused on the core business. Each new entity becomes a site for fresh capital formation and contributes to Signe's business growth and value. As an important benefit, this business structure encourages multiple clinical and commercial uses of each protein, which in turn substantially reduces market risk and maximizes profit potential.
